JP2022082779A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022082779A5 JP2022082779A5 JP2022064556A JP2022064556A JP2022082779A5 JP 2022082779 A5 JP2022082779 A5 JP 2022082779A5 JP 2022064556 A JP2022064556 A JP 2022064556A JP 2022064556 A JP2022064556 A JP 2022064556A JP 2022082779 A5 JP2022082779 A5 JP 2022082779A5
- Authority
- JP
- Japan
- Prior art keywords
- ophthalmic composition
- total content
- salts
- component
- total amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 239000000850 decongestant Substances 0.000 claims 5
- 210000003205 muscle Anatomy 0.000 claims 5
- 235000013343 vitamin Nutrition 0.000 claims 5
- 239000011782 vitamin Substances 0.000 claims 5
- 229940088594 vitamin Drugs 0.000 claims 5
- 229930003231 vitamin Natural products 0.000 claims 5
- 235000001014 amino acid Nutrition 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 239000002562 thickening agent Substances 0.000 claims 4
- 150000003722 vitamin derivatives Chemical class 0.000 claims 4
- 238000002360 preparation method Methods 0.000 claims 2
- BYJAVTDNIXVSPW-UHFFFAOYSA-N tetryzoline Chemical group N1CCN=C1C1C2=CC=CC=C2CCC1 BYJAVTDNIXVSPW-UHFFFAOYSA-N 0.000 claims 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 claims 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical group FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims 1
- 229920001287 Chondroitin sulfate Polymers 0.000 claims 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 150000004283 biguanides Chemical class 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims 1
- 229940059329 chondroitin sulfate Drugs 0.000 claims 1
- 229940124581 decongestants Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229960002362 neostigmine Drugs 0.000 claims 1
- LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical group [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 claims 1
- 239000002736 nonionic surfactant Substances 0.000 claims 1
- 229940101267 panthenol Drugs 0.000 claims 1
- 235000020957 pantothenol Nutrition 0.000 claims 1
- 239000011619 pantothenol Substances 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 229940037001 sodium edetate Drugs 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims 1
- 150000003505 terpenes Chemical class 0.000 claims 1
- 229960000337 tetryzoline Drugs 0.000 claims 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 1
- 229960000281 trometamol Drugs 0.000 claims 1
- 235000019155 vitamin A Nutrition 0.000 claims 1
- 239000011719 vitamin A Substances 0.000 claims 1
- 229940045997 vitamin a Drugs 0.000 claims 1
Claims (9)
前記充血除去剤が、テトラヒドロゾリン及びその塩であり、
前記眼筋調節剤が、ネオスチグミン及びその塩であり、
前記ビタミン剤が、パンテノール及びその塩であり、
前記アミノ酸類が、アスパラギン酸及びアミノエチルスルホン酸並びにそれらの塩であり、
前記増粘剤が、コンドロイチン硫酸及びその塩である、眼科組成物。 (A) 40,000 to 200,000 IU/100 mL of at least one selected from vitamin A, (B) at least one selected from the group consisting of butylhydroxyanisole and salts thereof, and (C) a decongestant , an ophthalmic composition containing at least one component selected from the group consisting of ocular muscle modulators , vitamins , amino acids and thickeners,
the decongestant is tetrahydrozoline and salts thereof;
the ocular muscle modulating agent is neostigmine and salts thereof ;
The vitamin preparation is panthenol and its salt,
the amino acids are aspartic acid and aminoethylsulfonic acid and salts thereof;
The ophthalmic composition, wherein the thickening agent is chondroitin sulfate and salts thereof .
前記眼科組成物が前記眼筋調節剤を含む場合、前記眼筋調節剤の総含有量は、前記眼科組成物の総量を基準として、０．０００１～０．１ｗ／ｖ％であり、When the ophthalmic composition contains the ocular muscle modulating agent, the total content of the ocular muscle modulating agent is 0.0001 to 0.1 w/v% based on the total amount of the ophthalmic composition,
前記眼科組成物が前記ビタミン剤を含む場合、前記ビタミン剤の総含有量は、前記眼科組成物の総量を基準として、０．００５～１ｗ／ｖ％であり、When the ophthalmic composition contains the vitamin agent, the total content of the vitamin agent is 0.005 to 1 w/v% based on the total amount of the ophthalmic composition,
前記眼科組成物が前記アミノ酸類を含む場合、前記アミノ酸類の総含有量は、前記眼科組成物の総量を基準として、０．０１～５ｗ／ｖ％であり、When the ophthalmic composition contains the amino acids, the total content of the amino acids is 0.01 to 5 w/v% based on the total amount of the ophthalmic composition,
前記眼科組成物が前記増粘剤を含む場合、前記増粘剤の総含有量は、前記眼科組成物の総量を基準として、０．０１～５ｗ／ｖ％である、請求項１又は２に記載の眼科組成物。When the ophthalmic composition contains the thickening agent, the total content of the thickening agent is 0.01 to 5 w/v% based on the total amount of the ophthalmic composition, according to claim 1 or 2 An ophthalmic composition as described.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016154576 | 2016-08-05 | ||
| JP2016154576 | 2016-08-05 | ||
| JP2017152727A JP7081909B2 (en) | 2016-08-05 | 2017-08-07 | Ophthalmic composition |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017152727A Division JP7081909B2 (en) | 2016-08-05 | 2017-08-07 | Ophthalmic composition |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022082779A JP2022082779A (en) | 2022-06-02 |
| JP2022082779A5 true JP2022082779A5 (en) | 2022-08-09 |
| JP7348347B2 JP7348347B2 (en) | 2023-09-20 |
Family
ID=61193606
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017152727A Active JP7081909B2 (en) | 2016-08-05 | 2017-08-07 | Ophthalmic composition |
| JP2022064556A Active JP7348347B2 (en) | 2016-08-05 | 2022-04-08 | Ophthalmic composition |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017152727A Active JP7081909B2 (en) | 2016-08-05 | 2017-08-07 | Ophthalmic composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (2) | JP7081909B2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7081909B2 (en) * | 2016-08-05 | 2022-06-07 | ロート製薬株式会社 | Ophthalmic composition |
| US20230037121A1 (en) * | 2021-07-16 | 2023-02-02 | Pegavision Corporation | Liquid composition for ophthalmic product |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05132421A (en) * | 1991-11-11 | 1993-05-28 | Lion Corp | Aqueous eye drop containing solubilized vitamin a |
| JP3199475B2 (en) * | 1992-07-21 | 2001-08-20 | ライオン株式会社 | Stabilization method of solubilized aqueous solution of vitamin A |
| JP3802328B2 (en) | 2000-09-25 | 2006-07-26 | ライオン株式会社 | Vitamin A solubilized aqueous solution and eye drops |
| JP2009173638A (en) | 2007-12-26 | 2009-08-06 | Lion Corp | Method of stabilizing ophthalmic composition and vitamin a family |
| JP2011021002A (en) | 2009-06-16 | 2011-02-03 | Lion Corp | Ophthalmic composition |
| CN102085395A (en) | 2009-12-02 | 2011-06-08 | 日本乐敦制药株式会社 | Ophthalmological composition for silicone hydrogel contact lens |
| JP2013133318A (en) | 2011-12-27 | 2013-07-08 | Lion Corp | Contact lens fitting liquid |
| JP6155863B2 (en) | 2012-06-08 | 2017-07-05 | ライオン株式会社 | Mucosal composition and method for producing the same |
| JP6179204B2 (en) | 2012-06-08 | 2017-08-16 | ライオン株式会社 | Mucosal composition and method for producing the same |
| CN103919718B (en) | 2013-01-11 | 2016-12-28 | 沈阳兴齐眼药股份有限公司 | A kind of vitamin A palmitate eye drop and its production and use |
| JP7081909B2 (en) * | 2016-08-05 | 2022-06-07 | ロート製薬株式会社 | Ophthalmic composition |
-
2017
- 2017-08-07 JP JP2017152727A patent/JP7081909B2/en active Active
-
2022
- 2022-04-08 JP JP2022064556A patent/JP7348347B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022082779A5 (en) | ||
| KR100347651B1 (en) | Antimicrobial treatment for herpes simplex virus and other infectious diseases | |
| JP2001158734A (en) | Composition for ophthalmology and method for inhibiting adsorption to soft contact lens | |
| JPH11130667A (en) | Ophthalmic composition for soft contact lens, wetting enhancement of soft contact lens and adsorption suppression of terpenoid | |
| JP2001187728A (en) | Ophthalmic composition | |
| JP2023168547A5 (en) | ||
| JP2013535472A5 (en) | ||
| JP2020073606A (en) | Eye drops for nonionic silicone hydrogel contact lenses | |
| JP2022003099A5 (en) | ||
| JP2001122774A (en) | Ophthalmic composition and method for suppressing adsorption on soft contact lens | |
| JP2023168547A (en) | Ophthalmic composition | |
| JP2003206241A (en) | Ophthalmic agent | |
| JP4099624B2 (en) | Composition for soft contact lenses | |
| JP3175742B1 (en) | Ophthalmic composition for contact lenses | |
| JP4355574B2 (en) | Eye drops | |
| JPWO2002085372A1 (en) | Drugs and drug kits | |
| MX2022015524A (en) | Crystalline forms of {2-[3-cyclohexyl-3-(trans-4-propoxy- cyclohexyl)-ureido]-thiazol-5-ylsulfanyl} -acetic acid and and uses thereof. | |
| JP2001253822A (en) | Corneal cell restorer composition | |
| JPH0780760B2 (en) | Stabilized phenylephrine liquid agent | |
| JP2003073303A (en) | Method for maintaining refreshing activity of eye drops | |
| JP5041761B2 (en) | Ocular mucosa application | |
| JP2001158750A (en) | Method for improving sustainability of ophthalmic composition and anti-allergic medicine | |
| JP2023009258A5 (en) | ||
| JPS588013A (en) | Pharmaceutical blend for remedy of glaucoma and high intraocular pressure disease | |
| BR9914418A (en) | Sertraline oral concentrate |